Sarepta sees early success with RNAi drugs from Arrowhead
BioPharma Dive
Long-awaited results from Phase 1/2 studies lifted Sarepta s stock and, according to the company, suggest potential for two medicines to treat muscle-weakening conditions.
pharminent
March 25, 2026 (Last updated: March 26, 2026)
BioPharma Dive
Long-awaited results from Phase 1/2 studies lifted Sarepta s stock and, according to the company, suggest potential for two medicines to treat muscle-weakening conditions.